Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dactinomycin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A known ✓ | P11388 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 5/20 | 0.62 |
| ▸ | MAPT | P10636 | 4/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.62 |
| ▸ | BLM | P54132 | 4/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.62 |
| ▸ | GRB2 | P62993 | 3/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.62 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.62 |
| ▸ | CASP1 | P29466 | 1/20 | 0.62 |
| ▸ | CASP7 | P55210 | 1/20 | 0.62 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.62 |
| ▸ | NGLY1 | Q96IV0 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dactinomycin SCHEMBL28208187 | 1.00 | RECQL (0.62) | RECQLMAPTSMN1; SMN2CYP3A4BLM | |
| Dactinomycin SCHEMBL27881861 | 1.00 | RECQL (0.62) | RECQLMAPTSMN1; SMN2CYP3A4BLM | |
| Dactinomycin SCHEMBL28142059 | 0.96 | GRB2 (0.61) | RECQLMAPTSMN1; SMN2CYP3A4BLM | |
| Dactinomycin SCHEMBL987923 | 0.96 | GRB2 (0.61) | RECQLMAPTSMN1; SMN2CYP3A4BLM | |
| Dactinomycin SCHEMBL28238143 | 0.93 | RECQL (0.54) | RECQLMAPTSMN1; SMN2CYP3A4BLM | |
| Dactinomycin SCHEMBL28212929 | 0.88 | MAPT (0.48) | RECQLMAPTSMN1; SMN2CYP3A4BLM | |
| Dactinomycin SCHEMBL28182665 | 0.87 | RECQL (0.47) | RECQLMAPTSMN1; SMN2CYP3A4BLM | |
| Dactinomycin SCHEMBL28243094 | 0.83 | MAPT (0.43) | RECQLMAPTSMN1; SMN2CYP3A4BLM | |
| Dactinomycin SCHEMBL3844 | 0.79 | GRB2 (1.00) | RECQLMAPTSMN1; SMN2CYP3A4BLM | |
| Dactinomycin SCHEMBL6152 | 0.79 | GRB2 (1.00) | RECQLMAPTSMN1; SMN2CYP3A4BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012158197-A2 | COMPOUNDS USEFUL AS AKT/PKB MODULATORS AND USES THEREOF | LYNDOR BIOSCIENCES L.L.C. (US) | 2012-11-22 | — | — | WO | claimed |
| US-20090028855-A1 | INHIBITORS OF AKT/PKB WITH ANTI-TUMOR ACTIVITY | UNIVERSITY OF SOUTH FLORIDA (US) | 2009-01-29 | — | — | US | claimed |
| CN-117980327-A | Specific coupling of antibodies | 杭州多禧生物科技有限公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-114555123-B | Combination therapy for the treatment of myelodysplastic syndrome and acute myeloid leukemia | 四十七公司 | 2024-04-02 | — | — | CN | disclosed |
| WO-2012158197-A2 | COMPOUNDS USEFUL AS AKT/PKB MODULATORS AND USES THEREOF | LYNDOR BIOSCIENCES L.L.C. (US) | 2012-11-22 | — | — | WO | disclosed |
| WO-2009093012-A1 | INDOLYL- PYRIDONE DERIVATIVES HAVING CHECKPOINT KINASE 1 INHIBITORY ACTIVITY | VERNALIS (R & D) LTD (GB) | 2009-07-30 | — | — | WO | disclosed |
| EP-1742920-A2 | NAPHTHALIMIDE DERIVATIVES FOR THE TREATMENT OF CANCER | Unibioscreen S.A. (BE) | 2007-01-17 | — | — | EP | disclosed |
| WO-2005105753-A2 | NAPHTHALIMIDE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS THEREFROM | UNIBIOSCREEN S.A. (BE) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090028855-A1 | INHIBITORS OF AKT/PKB WITH ANTI-TUMOR ACTIVITY | AKT1, AKT2, MTOR | TOP2A 3280/4885RECQL 3978/4885MAPT 4404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.